Marker Therapeutics - Our Science
Our Science
MultiTAA Technology

Marker’s Multi-Antigen Targeted (MultiTAA) technology utilizes a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s blood capable of recognizing a broad range of tumor antigens. In early clinical trials, the multi-antigen approach has been well-tolerated and shown to enhance tumor killing capability.

Typical Cell Therapy Approach
Our MultiTAA Approach

MultiTAA Tabs

Targets Multiple
Tumor Antigens

Marker’s unique MultiTAA technology differs significantly from today’s leading cell therapies, which are genetically engineered to recognize a single portion (or epitope) of a single tumor-associated antigen. MultiTAA-specific T cells recognize up to six antigens for a potent, durable anti-tumor response.

Broad, Durable
Anti-Tumor Effect

MultiTAA-specific therapies consistently demonstrate epitope spreading – inducing the patient’s own T cells to expand, potentially contributing to a lasting anti-tumor effect.


MultiTAA-specific T cell therapies have been well-tolerated in clinical trials to date and may have reduced toxicities compared to current engineered CAR-T and T cell receptor-based therapies.

T Cells

MultiTAA-specific T cell therapies, which are based on the selective expansion of a patient’s natural T cells and are not genetically engineered, carry no mutagenesis risk.


MultiTAA-specific T cells are significantly less expensive to manufacture than genetically engineered T cells. The cell manufacturing process is efficient and scalable.


Unlike other cell therapies which require pre-conditioning regimens and hospitalization, MultiTAA-specific T cell therapies are designed to be administered in an outpatient setting.